Aberrant chromatin regulatory cues promote oncogenic signaling and inactivate tumor suppressor function in cancer cells. Moreover, epigenetic alterations promote evasion from immunosurveillance by altering cellular and molecular processes that are essential for the development of anti-tumor responses. The latter processes include tumor antigen expression, processing and presentation, expression of co-stimulatory and inhibitory checkpoint receptors, secretion of immunosuppressive factors, as well as differentiation and function of effector and suppressive immune cell subsets. While it remains an ongoing challenge to identify the genomic, epigenomic and transcriptional contexts that renders cancer and immune cells dependent on individual chromatin regulators some of these enzymes have clearly emerged as candidate oncology targets and have raised significant interest in the drug discovery community.

Selective modulation of chromatin regulatory pathways has profound consequences in cancer cells and immune cells.

Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge, MA 02142

For Media Inquiries
Katie Engleman
+1 (910) 509-3977

For General Inquires
To request additional information please use:
Phone: (617) 714-0555
Fax: (617) 577-0472